Pre-clinical studies show that BRAFi increase the expression of the IFNAR1 receptor on BRAF-mutant tumor cells, potentiating the activity of IFN (Sabbatino et al., 2016), and a phase I study combining IFN with vemurafenib plus cobimetinib demonstrated the safety of this triple therapy in the clinic (Simeone et al., 2021). Here, BRAF is linked to neoplasm.